Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 1Q11

Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 1Q11

1Q Revenues: $9.0 billion (+17%)

1Q Earnings: $864.0 million (-14%)

Comments: Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion. Trilipix/TriCor sales were $372 million, up 28%. Kaletra sales dropped 15% to $248 million. Niaspan sales were up 11% to $226 million. Synthroid sales were $145 million, up 18%. R&D expenses were up 27% to $930 million. Medical device sales were $1.2 billion (+11%). Earnings were impacted by restructuring and integration costs for the Solvay Pharmaceuticals acquistion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters